Bacharach, Jason http://orcid.org/0000-0002-7084-4327
Doan, Long V. http://orcid.org/0009-0008-0572-2236
Stephens, Kerry G.
Usner, Dale W. http://orcid.org/0000-0002-2799-0652
Kothe, Angela C. http://orcid.org/0009-0000-7971-5292
Katz, L. Jay
Navratil, Tomas http://orcid.org/0009-0007-3577-3096
Article History
Received: 17 May 2024
Accepted: 24 June 2024
First Online: 10 July 2024
Declarations
:
: Jason Bacharach is a consultant/advisor for Glaukos Corporation and Allergan, Inc., has received research funding from Glaukos Corporation, and has received lecture fees/honoraria from Allergan, Inc. Long V. Doan, Kerry G. Stephens, Angela C. Kothe, L. Jay Katz and Tomas Navratil are employees of Glaukos Corporation and may hold stock and/or stock options. Dale W. Usner was an employee of Glaukos Corporation at the time this analysis was conducted and held stock and/or stock options, and is currently a consultant for Glaukos Corporation.
: Human Subjects: Human subjects were included in these trials. The trials were registered at ClinicalTrials.gov (NCT03519386 and NCT03868124) and were performed in accordance with the tenets of the Declaration of Helsinki of 1964 and its later amendments, and with approval of the relevant Institutional Review Board/Independent Ethics Committee (for GC-010: WCG Institutional Review Board, Puyallup, Washington [reference number 20180735] or Wills Eye Hospital Institutional Review Board, Philadelphia, Pennsylvania [reference number 18–763] for sites in the USA, and St. Cabrini Medical Center—Asian Eye Institute Ethics Review Committee, Makati City, Philippines [reference number 2018–023] for the single site in the Philippines; for GC-012: WCG Institutional Review Board, Puyallup, Washington [reference number 20181794] for sites in the USA and the Ethics Committee of Ophthalmological Center named after S.V. Malayan, Yerevan, Armenia [approved on January 16, 2020] for the single site in Armenia). All subjects provided informed consent to participate in the study.